Some gene arrangements often recur in specific sarcoma types, e.g., SS18–SSX1 in synovial sarcoma and EWSR1–FLI1 in Ewing sarcoma, making these hallmark gene fusions ideal biomarkers in diagnosing and monitoring minimal residual diseases [2]. This evidence concerns the gene FLI1 and sarcoma.